Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Lionetti R, Calvaruso V, Piccolo P, Mancusi RL, Mazzarelli C, Fagiuoli S, Montalbano M, Lenci I, Carrai P, Guaraldi G, Visco-Comandini U, Milana M, Biolato M, Loiacono L, Valente G, Craxì A, Angelico M, D'offizi G.
Lionetti R, et al. Among authors: mazzarelli c.
Clin Transplant. 2018 Feb;32(2). doi: 10.1111/ctr.13165. Epub 2017 Dec 18.
Clin Transplant. 2018.
PMID: 29193356